Keep up with the latest in the tableting community!
March 23, 2021
Reducing “time to market” is the ultimate goal
for every pharmaceutical lab. Being the first on
the market brings a competitive advantage for
prescription, over-the-counter, or generic-drug
manufacturers. Applying quality-by-design
(QbD) principles at the formulation phase can
prevent tablet defects at an early stage and
thereby drastically reduce time during the
complex and troublesome phase of “scale-up”.
March 3, 2021
UCB's announced a new partnership in order to integrate IA technologies as a tool for its development.The aim is to "significantly accelerate the iteration cycles required to identify more effective molecules".
The complete Press article can be found here.